549 related articles for article (PubMed ID: 30921051)
21. Resection after neoadjuvant therapy for locally advanced, "unresectable" pancreatic cancer.
Strobel O; Berens V; Hinz U; Hartwig W; Hackert T; Bergmann F; Debus J; Jäger D; Büchler MW; Werner J
Surgery; 2012 Sep; 152(3 Suppl 1):S33-42. PubMed ID: 22770956
[TBL] [Abstract][Full Text] [Related]
22. Prognostic Factors in Patients With Borderline Resectable Pancreatic Ductal Adenocarcinoma Undergoing Resection.
Ren W; Xourafas D; Ashley SW; Clancy TE
Am Surg; 2022 Jun; 88(6):1172-1180. PubMed ID: 33522271
[TBL] [Abstract][Full Text] [Related]
23. Clinical impacts of resection margin status and clinicopathologic parameters on pancreatic ductal adenocarcinoma.
Jamiyan T; Shiraki T; Kurata Y; Ichinose M; Kubota K; Imai Y
World J Surg Oncol; 2020 Jun; 18(1):137. PubMed ID: 32571348
[TBL] [Abstract][Full Text] [Related]
24. Poorly differentiated resectable pancreatic cancer: is upfront resection worthwhile?
Crippa S; Partelli S; Zamboni G; Barugola G; Capelli P; Inama M; Bassi C; Pederzoli P; Falconi M
Surgery; 2012 Sep; 152(3 Suppl 1):S112-9. PubMed ID: 22766365
[TBL] [Abstract][Full Text] [Related]
25. The impact of margin status determined by the one-millimeter rule on tumor recurrence and survival following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.
Nitta T; Nakamura T; Mitsuhashi T; Asano T; Okamura K; Tsuchikawa T; Tamoto E; Murakami S; Noji T; Kurashima Y; Ebihara Y; Nakanishi Y; Shichinohe T; Hirano S
Surg Today; 2017 Apr; 47(4):490-497. PubMed ID: 27677294
[TBL] [Abstract][Full Text] [Related]
26. Pancreatic adenocarcinoma: A simple CT score for predicting margin-positive resection in patients with resectable disease.
Cassinotto C; Dohan A; Zogopoulos G; Chiche L; Laurent C; Sa-Cunha A; Cuggia A; Reinhold C; Gallix B
Eur J Radiol; 2017 Oct; 95():33-38. PubMed ID: 28987689
[TBL] [Abstract][Full Text] [Related]
27. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy.
Barugola G; Partelli S; Crippa S; Capelli P; D'Onofrio M; Pederzoli P; Falconi M
Am J Surg; 2012 Feb; 203(2):132-9. PubMed ID: 21824596
[TBL] [Abstract][Full Text] [Related]
28. Preoperative prediction of disease-free survival in pancreatic ductal adenocarcinoma patients after R0 resection using contrast-enhanced CT and CA19-9.
Li D; Peng Q; Wang L; Cai W; Liang M; Liu S; Ma X; Zhao X
Eur Radiol; 2024 Jan; 34(1):509-524. PubMed ID: 37507611
[TBL] [Abstract][Full Text] [Related]
29. Microscopically positive (R1) resections do not affect survival in pancreatic head cancer.
Mois E; Graur F; Al-Hajjar N; Zaharie F; Bartos A; Bodea R; Zaharie T; Rusu I; Iancu C
Ann Ital Chir; 2017; 88():491-496. PubMed ID: 29339587
[TBL] [Abstract][Full Text] [Related]
30. Cancer outcomes are independent of preoperative CA 19-9 in anatomically resectable pancreatic ductal adenocarcinoma: A retrospective cohort analysis.
Kim JK; DePeralta DK; Ogami T; Denbo JW; Pimiento J; Hodul PJ; Malafa MP; Kim DW; Fleming JB; Powers BD
J Surg Oncol; 2020 Nov; 122(6):1074-1083. PubMed ID: 32673436
[TBL] [Abstract][Full Text] [Related]
31. Oligometastatic pulmonary metastasis in pancreatic cancer patients: Safety and outcome of resection.
Ilmer M; Schiergens TS; Renz BW; Schneider C; Sargut M; Waligora R; Weniger M; Hartwig W; Ceyhan GO; Friess H; Werner J; D'Haese JG
Surg Oncol; 2019 Dec; 31():16-21. PubMed ID: 31473583
[TBL] [Abstract][Full Text] [Related]
32. Contemporary Reappraisal of Intraoperative Neck Margin Assessment During Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: A Review.
Datta J; Willobee BA; Ryon EL; Shah MM; Drebin JA; Kooby DA; Merchant NB
JAMA Surg; 2021 May; 156(5):489-495. PubMed ID: 33533898
[TBL] [Abstract][Full Text] [Related]
33. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
Addeo P; Rosso E; Fuchshuber P; Oussoultzoglou E; De Blasi V; Simone G; Belletier C; Dufour P; Bachellier P
Oncology; 2015; 89(1):37-46. PubMed ID: 25766660
[TBL] [Abstract][Full Text] [Related]
34. Predictive factors for long-term survival after surgery for pancreatic ductal adenocarcinoma: Making a case for standardized reporting of the resection margin using certified cancer center data.
Weyhe D; Obonyo D; Uslar VN; Stricker I; Tannapfel A
PLoS One; 2021; 16(3):e0248633. PubMed ID: 33735191
[TBL] [Abstract][Full Text] [Related]
35. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial.
Neoptolemos JP; Stocken DD; Dunn JA; Almond J; Beger HG; Pederzoli P; Bassi C; Dervenis C; Fernandez-Cruz L; Lacaine F; Buckels J; Deakin M; Adab FA; Sutton R; Imrie C; Ihse I; Tihanyi T; Olah A; Pedrazzoli S; Spooner D; Kerr DJ; Friess H; Büchler MW;
Ann Surg; 2001 Dec; 234(6):758-68. PubMed ID: 11729382
[TBL] [Abstract][Full Text] [Related]
36. Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma.
Boone BA; Steve J; Zenati MS; Hogg ME; Singhi AD; Bartlett DL; Zureikat AH; Bahary N; Zeh HJ
Ann Surg Oncol; 2014 Dec; 21(13):4351-8. PubMed ID: 25092157
[TBL] [Abstract][Full Text] [Related]
37. Frozen section of the pancreatic neck margin in pancreatoduodenectomy for pancreatic adenocarcinoma is of limited utility.
Pang TC; Wilson O; Argueta MA; Hugh TJ; Chou A; Samra JS; Gill AJ
Pathology; 2014 Apr; 46(3):188-92. PubMed ID: 24614707
[TBL] [Abstract][Full Text] [Related]
38. Preoperative cognitive function predicts survival in patients with resectable pancreatic ductal adenocarcinoma.
Baekelandt BM; Hjermstad MJ; Nordby T; Fagerland MW; Kure EH; Heiberg T; Buanes T; Labori KJ
HPB (Oxford); 2016 Mar; 18(3):247-54. PubMed ID: 27017164
[TBL] [Abstract][Full Text] [Related]
39. Pancreatic resection for M1 pancreatic ductal adenocarcinoma.
Shrikhande SV; Kleeff J; Reiser C; Weitz J; Hinz U; Esposito I; Schmidt J; Friess H; Büchler MW
Ann Surg Oncol; 2007 Jan; 14(1):118-27. PubMed ID: 17066229
[TBL] [Abstract][Full Text] [Related]
40. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]